Statistical considerations for COPD exacerbation trials

Chronic Obstructive Pulmonary Disease Exacerbations

Volumn , Issue , 2008, Pages 407-416

  Aaron, Shawn D ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899422250     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (21)

1. Anthonisen NR, Connet JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
2. Mahler DA, Barbee RA, Gross NJ, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
3. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004; 98(2): 99-107 (review).
4. Slymen D, Ayala G, Arredondo EM, et al. Analytic perspective: a demonstration of modeling count data with an application to physical activity. Epidemiol Perspect Innnov 2006; 3(3): 1-9.
5. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
6. Aaron SD, Vandemheen K, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone/salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555. (epub 2007, Feb 19).
7. Suisa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842-846.
8. Aaron SD, Fergusson D, Marks GB, et al. Counting, analyzing and reporting exacerbations of COPD in randomized, controlled trials. Thorax 2008; 63: 122-128.
9. Keene ON, Jones MRK, Lane PW, et al. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat 2007; 6: 89-97.
10. Spencer S, Jones PW. Globe Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58(7): 589-593.
11. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.
12. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134(8): 657-662.
13. Kesten S, Plautz M, Piquette CA, et al. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J 2007; 30(5): 898-906.
14. Niewoehner DE, Rice KL, Cote CG, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med 2005; 143: 317-326.
15. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically usefulmeasures of the consequences of treatment. N Engl J Med 1988; 318: 1728-1733.
16. Altman DG. Confidence intervals for the number needed to treat. Br Med J 1998; 317: 1309-1312.
17. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995; 310: 452-454.
18. Halpin DMG. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int J Clin Pract 2005; 59(10): 1187-1194.
19. Cazzola M. Application of Number Needed to Treat (NNT) as a measure of treatment effect in respiratory medicine. Treat Respir Med 2006; 5(2): 79-84.
20. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstuctive pulmonary disease. NEJM 2007; 356(8): 775-789.
21. Kardos P, WenckerM, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit CareMed 2007; 175: 144-149.